Intimation of Analyst and Investor call under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 scheduled to be held on 5th November, 2026

October 29, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejebhoy Towers “Exchange Plaza” Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai - 400051 Scrip Code (BSE): 544009 Symbol: BLUEJET Sub: Intimation of Analyst and Investor call under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir / Ma'am, In terms of the referred Regulation 30 read with Schedule III - Part A of SEBI Listing Regulations, 2015, we would like to inform you that a conference call for group of analysts and investors has been scheduled on Thursday, November 5, 2026 at 5:00 PM (IST) to discuss the Unaudited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2026. Details of the conference call are enclosed for your kind reference. You are requested to take the same on record. Thanking you, Yours faithfully, For Blue Jet Healthcare Limited Sweta Poddar Company Secretary & Compliance Officer Membership No: F12287 PRESS RELEASE For Immediate dissemination Blue Jet Healthcare Limited Q2 & H1 FY27 Earnings Call on November 05, 2026, at 5:00 PM IST Mumbai, November 02, 2026: Blue Jet Healthcare Ltd. (BSE- 544009, NSE- BLUEJET, ISIN: INE0KBH01020), a global, science-led, pharmaceutical company evolved as Strategic Partner for Collaboration, Development & Manufacturing of advance Pharmaceutical Intermediates and API, will host earnings call to discuss financial results for the quarter and half year ended 30th September 2026 on Thursday, November 05, 2026, at 5:00 PM (IST). Details of Earnings Conference Call Day/Date Thursday, November 05, 2026 Time (IST) 5:00 PM Universal Access +91 22 6280 1107 +91 22 7115 8008 The number listed above is universally accessible from all networks and all countries International Toll-Free Numbers USA 18667462133 UK 08081011573 Singapore 8001012045 Hong Kong 800964448 DiamondPass™ Link Click here to join with DiamondPass™ (No Wait Time) Management Representation: Mr. Shiven Arora - Managing Director Mr. V.K. Singh - Chief Operating Officer Mr. Ganesh Karuppannan - Chief Financial Officer Mr. Sanjay Sinha - Deputy Chief Financial Officer Participants are requested to dial-in 10 minutes before the scheduled time About Blue Jet Healthcare Ltd: Blue Jet Healthcare Ltd a specialty pharmaceutical and healthcare ingredient and intermediate company, operating under a contract development and manufacturing organization (“CDMO”) business model. The company has specialized chemistry capabilities in contrast media intermediates and high-intensity sweeteners. They have built a long-term customer base with innovator and multi-national generic pharmaceutical companies, supported by multi-year contracts. They supply a critical starting intermediate and several advanced intermediates to three of the largest contrast media manufacturers in the world, including GE Healthcare, Guerbet, and Bracco. They also supply high-intensity sweeteners to several multi-national companies, including Colgate Palmolive (India) Limited and Unilever. For further details, please get in touch with: Ms. Sweta Poddar Diwakar Pingle | Kunal Bhoite Blue Jet Healthcare Ltd EY Investor Relations Email: companysecretary@bluejethealthcare.com Email: diwakar.pingle@in.ey.com | kunal.bhoite@in.ey.com